Dr Peter Campbell

Dr Peter Campbell is Head of Cancer Genetics and Genomics at the Institute and is joint head of the Cancer Genome Project. His research focuses on the use of next-generation sequencing technologies for annotating cancer genomes.

He is also a practising haematologist at Addenbrooke's Hospital in Cambridge.

After completing his specialist training in Haematology in 2002 in Australia and New Zealand, Peter earned his PhD into the molecular pathogenesis and clinical management of myeloproliferative disorders at the University of Cambridge. Peter remains co-clinical lead on the largest randomised clinical trial in essential thrombocythaemia, a common chronic haematological malignancy.

In 2007 Peter moved to the Sanger Institute where he joined the Cancer Genome Project on a Kay Kendall Leukaemia Fund Clinical Fellowship. Since joining the Institute, he has pioneered the development of protocols for identifying somatically acquired mutations from massively parallel sequencing data. In 2009 Peter was senior author on the first complete high-coverage sequence and analysis of a whole cancer genome associated with tobacco smoke exposure.

Peter's current major interests are in the large-scale sequencing of cancer genomes, development of informatic tools for the integration and analysis of genomic data sets in cancer and the translation of advances in genomic technologies into improvements in the clinical management of patients with cancer.

Peter joined the Institute's Faculty of Researchers in 2010 with the award of a Wellcome Trust Senior Clinical Research Fellowship. He is a Fellow of the Royal Australian College of Physicians and the Royal College of Pathologists of Australia.

Selected Publications

  • A small-cell lung cancer genome with complex signatures of tobacco exposure.

    Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordoñez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA and Campbell PJ

    Nature 2010;463;7278;184-90

  • The cancer genome.

    Stratton MR, Campbell PJ and Futreal PA

    Nature 2009;458;7239;719-24

  • Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing.

    Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, Follows GA, Green AR, Futreal PA and Stratton MR

    Proceedings of the National Academy of Sciences of the United States of America 2008;105;35;13081-6

  • Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

    Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, Stebbings LA, Leroy C, Edkins S, Hardy C, Teague JW, Menzies A, Goodhead I, Turner DJ, Clee CM, Quail MA, Cox A, Brown C, Durbin R, Hurles ME, Edwards PA, Bignell GR, Stratton MR and Futreal PA

    Nature genetics 2008;40;6;722-9

  • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

    Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party and Australasian Leukaemia and Lymphoma Group

    Lancet (London, England) 2005;366;9501;1945-53

[Genome Research Limited]

Peter's Project
Cancer Genome Project
Research Area
Human genetics
* quick link - http://q.sanger.ac.uk/doj15jp5